Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Primary Purpose : Treatment
Allocation : Randomized
Interventional Model : Parallel Assignment
Interventional Model Description: Randomized Controlled Trial
Masking : Triple (Participant, Care Provider, Investigator)
Primary outcome measures:
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose, Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
The authors concluded that in the acute treatment of migraine, a single 75 mg dose of rimegepant in an orally disintegrating tablet formulation was more effective than a placebo. Tolerability was similar to that of the placebo, with no safety concerns.
…